Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus PENECORT.
ADVAIR DISKUS 100/50 vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid